Reporting the counterparty's growth as its own: management explains the company's coming year by narrating what its cust
The model's full reasoning — Q3 2023 call → NOThe question asks whether management explains the company's business direction by narrating what its counterparties are themselves doing and scaling. I need to check if the transcript shows management speaking about counterparties' growth as the driver of IceCure's own coming activity. Looking at the transcript, management discusses: - Distributors in various countries (Portugal, Brazil, China, Japan) - Terumo in Japan working on regulatory approval - Independent studies being conducted by doctors using ProSense - Sales increases in the U.S. and China However, the forward-looking statements are mostly about: - FDA appeal process and regulatory approvals - ICE3 trial completion - Their own sales and marketing efforts - Hiring a VP of sales for North America When management discusses counterparties like Terumo, they say Terumo is "working to get the regulatory approval" — this is contingent on approval, not yet flowing. The distributor in Portugal was just signed. Brazil is just starting. The independent studies are conducted by doctors, but these aren't described as a scaling trajectory that drives IceCure's volume — they're described as evidence supporting adoption. Management's forward account is primarily about regulatory outcomes (FDA appeal, ICE3 completion) and their own commercial efforts, not about counterparties' own expansion trajectories that IceCure is already embedded in and will ride. The counterparties mentioned (Terumo, distributors) are either awaiting regulatory approval (not yet flowing) or just signed (not yet scaled). The demand question is not settled for these — Terumo's sales haven't started. Answer: NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| EMKR | EMCORE Corporation | Q4 2023 | 2023-12-12 | C+ |
| MBLY | Mobileye Global Inc. | Q2 2023 | 2023-07-28 | B+ |
| PI | Impinj, Inc. | Q4 2022 | 2023-02-08 | B+ |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| OOMA | Ooma, Inc. | Q3 2022 | 2021-12-02 | B+ |
| ILMN | Illumina, Inc. | Q1 2018 | 2018-04-24 | A |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| FNV | Franco-Nevada Corporation | Q3 2016 | 2016-11-08 | B+ |
| HXL | Hexcel Corporation | Q4 2015 | 2016-01-22 | B+ |
OOMA · Q3 2022 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future volume as a consequence of those parties' trajectories.
MBLY · Q2 2023 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's volume as a consequence of those parties' trajectories.
ILMN · Q1 2018 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future as a consequence of those parties' trajectories.